# Ezra E.W. Cohen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ezra-e-w-cohen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 38,477 |
| Field | Head and Neck Cancer Studies |
| h-index | 85 |
| i10-index | 304 |
| Last Known Institution | Moores Cancer Center |
| OpenAlex ID | https://openalex.org/A5001334189 |
| ORCID iD | https://orcid.org/0000-0002-9872-6242 |
| Works | 862 |

## Researcher papers

- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)
- [Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group](https://scholariq.org/papers/meta-analysis-of-chemotherapy-in-head-and-neck-cancer-mach-nc-an-update-on-107/)
- [Positive Surgical Margins in the 10 Most Common Solid Cancers](https://scholariq.org/papers/positive-surgical-margins-in-the-10-most-common-solid-cancers/)
- [Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands](https://scholariq.org/papers/phase-ii-study-of-lapatinib-in-recurrent-or-metastatic-epidermal-growth-factor/)
- [Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial](https://scholariq.org/papers/pembrolizumab-plus-cetuximab-in-patients-with-recurrent-or-metastatic-head-and/)
- [Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity](https://scholariq.org/papers/evidence-based-clinical-practice-guideline-for-the-evaluation-of-potentially/)
- [Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: A systematic review and meta-analysis](https://scholariq.org/papers/prognostic-role-of-pretreatment-plasma-fibrinogen-in-patients-with-solid-tumors/)
- [Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics](https://scholariq.org/papers/immune-modulation-of-head-and-neck-squamous-cell-carcinoma-and-the-tumor/)

## Researcher topics

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Moores Cancer Center](https://scholariq.org/institutions/moores-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.